NY-ESO-1 DARPin

NY-ESO-1 DARPin refers to an **investigational Designed Ankyrin Repeat Protein** that binds the peptide-major histocompatibility complex formed by the **NY-ESO-1 157-165 peptide presented on HLA-A*0201**, rather than the intracellular NY-ESO-1 protein itself. Reported examples have been developed as targeting modules for **bispecific DARPin T-cell engagers** that pair an NY-ESO-1 peptide-HLA binder with a **CD3 epsilon-binding DARPin** to redirect T cells against NY-ESO-1-positive tumor cells. This appears to be a **research-stage targeting construct/platform component rather than a single clearly defined clinical drug product**, with published work describing potent and selective recognition of HLA-A*0201/NY-ESO-1-positive tumor targets, but without a clearly established standalone commercial product name, brand name, or broadly recognized development program under the exact name queried.

Other names

NY-ESO-1-specific DARPinNY-ESO1-specific DARPinNY-ESO 1-specific DARPinHLA-A*0201/NY-ESO-1 157-165-specific DARPin